organization · Reporting owner

Lynx1 Capital Management LP

Disclosed activity across 5 companies

Tapewire entity: 23615
SEC CIK: 0001910456

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Cullinan Therapeutics, Inc.CGEM · Entity 4766	10% owner	October 28, 2025	October 30, 2025
Korro Bio, Inc.KRRO · Entity 6388	10% owner	August 06, 2026	August 13, 2026
Neuphoria Therapeutics Inc.NEUP · Entity 7639	10% owner	October 21, 2025	October 23, 2025
Passage BIO, Inc.PASG · Entity 7829	10% owner	June 25, 2026	June 29, 2026
TScan Therapeutics, Inc.TCRX · Entity 7255	10% owner	December 19, 2025	December 23, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Cullinan Therapeutics, Inc.

Report date October 28, 2025 · Filed October 30, 2025

Jointly reported with Nichols Weston

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common stock, $0.0001 par value per shareSEC Table I · non-derivative	IndirectSee footnote	8,963,500	Reported balance After 2025-10-28 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2025-10-28 · Purchase · Acquired 165,667 · Balance 8,963,500 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.035 to $8.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F2: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.035 to $8.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F2: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.

Korro Bio, Inc.

Report date August 06, 2026 · Filed August 13, 2026

Jointly reported with Nichols Weston

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common stock, $0.001 par value per shareSEC Table I · non-derivative	IndirectSee footnote	1,544,980	Last balance in matching sequence After 2026-08-10 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2026-08-06 · Purchase · Acquired 5,222 · Balance 1,543,518 F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.39 to $11.40 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F1: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. Row 2 · 2026-08-10 · Purchase · Acquired 1,462 · Balance 1,544,980 F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.11 to $13.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F1: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.

F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.39 to $11.40 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.11 to $13.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

Neuphoria Therapeutics Inc.

Report date October 21, 2025 · Filed October 23, 2025

Jointly reported with Nichols Weston

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common stock, $0.00001 par value per shareSEC Table I · non-derivative	IndirectSee footnote	875,328	Reported balance After 2025-10-21 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2025-10-21 · Purchase · Acquired 639,110 · Balance 875,328 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.96 to $5.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F2: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.96 to $5.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

Passage BIO, Inc.

Report date June 25, 2026 · Filed June 29, 2026

Jointly reported with Nichols Weston

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common stock, $0.0001 par value per share ("Common Stock")SEC Table I · non-derivative	IndirectSee footnote	673,759	Reported balance After 2026-06-25 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2026-06-25 · Purchase · Acquired 50,055 · Balance 673,759 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.33 to $4.30 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F2: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.33 to $4.30 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

TScan Therapeutics, Inc.

Report date December 19, 2025 · Filed December 23, 2025

Jointly reported with Nichols Weston

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common stock, $0.0001 par value per share ("Common Stock")SEC Table I · non-derivative	IndirectSee footnote	7,937,416	Reported balance After 2025-12-19 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2025-12-19 · Purchase · Acquired 80,069 · Balance 7,937,416 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8862 to $0.90, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F2: The securities to which this filing relates are held directly by Lynx1 Master Fund LP and a managed account to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.
Common StockSEC Table I · non-derivative	IndirectSee footnote	8,019,148	Last balance in matching sequence After 2025-12-23 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 2 · 2025-12-22 · Purchase · Acquired 75,500 · Balance 8,012,916 F2: The securities to which this filing relates are held directly by Lynx1 Master Fund LP and a managed account to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. Row 3 · 2025-12-23 · Purchase · Acquired 6,232 · Balance 8,019,148 F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8958 to $0.90, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F2: The securities to which this filing relates are held directly by Lynx1 Master Fund LP and a managed account to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8862 to $0.90, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F2: The securities to which this filing relates are held directly by Lynx1 Master Fund LP and a managed account to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.

F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8958 to $0.90, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 10, 2026 Filed Aug 13, 2026 13:54 UTC	Korro Bio, Inc. KRRO · Entity 6388	PurchaseCommon stock, $0.001 par value per share	1,462	$13.19	$19,279.25	Disclosure SEC source: 0000902664-26-003434 · ownership.xml · nonDerivative · entry 2 Lynx1 Capital Management LP · CIK 0001910456 · 10% owner Nichols Weston · CIK 0001746376 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,544,980 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.11 to $13.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F1 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. Read SEC document
August 06, 2026 Filed Aug 13, 2026 13:54 UTC	Korro Bio, Inc. KRRO · Entity 6388	PurchaseCommon stock, $0.001 par value per share	5,222	$11.40	$59,529.76	Disclosure SEC source: 0000902664-26-003434 · ownership.xml · nonDerivative · entry 1 Lynx1 Capital Management LP · CIK 0001910456 · 10% owner Nichols Weston · CIK 0001746376 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,543,518 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.39 to $11.40 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F1 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. Read SEC document
June 25, 2026 Filed Jun 29, 2026 20:30 UTC	Passage BIO, Inc. PASG · Entity 7829	PurchaseCommon stock, $0.0001 par value per share ("Common Stock")	50,055	$4.12	$206,101.46	Disclosure SEC source: 0000902664-26-002945 · ownership.xml · nonDerivative · entry 1 Lynx1 Capital Management LP · CIK 0001910456 · 10% owner Nichols Weston · CIK 0001746376 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 673,759 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.33 to $4.30 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F2 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. Read SEC document
March 31, 2026 Filed Apr 2, 2026 16:00 UTC	Korro Bio, Inc. KRRO · Entity 6388	PurchaseCommon stock, $0.001 par value per share	520	$10.60	$5,512.00	Disclosure SEC source: 0000902664-26-001845 · ownership.xml · nonDerivative · entry 1 Lynx1 Capital Management LP · CIK 0001910456 · 10% owner Nichols Weston · CIK 0001746376 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,538,296 F1 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. Read SEC document
December 23, 2025 Filed Dec 23, 2025 23:17 UTC	TScan Therapeutics, Inc. TCRX · Entity 7255	PurchaseCommon Stock	6,232	$0.90	$5,601.94	Disclosure SEC source: 0000902664-25-005396 · ownership.xml · nonDerivative · entry 3 Lynx1 Capital Management LP · CIK 0001910456 · 10% owner Nichols Weston · CIK 0001746376 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 8,019,148 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8958 to $0.90, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F2 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP and a managed account to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. Read SEC document
December 22, 2025 Filed Dec 23, 2025 23:17 UTC	TScan Therapeutics, Inc. TCRX · Entity 7255	PurchaseCommon Stock	75,500	$0.90	$67,950.00	Disclosure SEC source: 0000902664-25-005396 · ownership.xml · nonDerivative · entry 2 Lynx1 Capital Management LP · CIK 0001910456 · 10% owner Nichols Weston · CIK 0001746376 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 8,012,916 F2 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP and a managed account to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. Read SEC document
December 19, 2025 Filed Dec 23, 2025 23:17 UTC	TScan Therapeutics, Inc. TCRX · Entity 7255	PurchaseCommon stock, $0.0001 par value per share ("Common Stock")	80,069	$0.90	$71,974.02	Disclosure SEC source: 0000902664-25-005396 · ownership.xml · nonDerivative · entry 1 Lynx1 Capital Management LP · CIK 0001910456 · 10% owner Nichols Weston · CIK 0001746376 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 7,937,416 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8862 to $0.90, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F2 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP and a managed account to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. Read SEC document
October 28, 2025 Filed Oct 30, 2025 21:13 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	PurchaseCommon stock, $0.0001 par value per share	165,667	$8.40	$1,391,685.63	Disclosure SEC source: 0000902664-25-004662 · ownership.xml · nonDerivative · entry 1 Lynx1 Capital Management LP · CIK 0001910456 · 10% owner Nichols Weston · CIK 0001746376 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 8,963,500 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.035 to $8.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F2 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. Read SEC document
October 21, 2025 Filed Oct 23, 2025 23:49 UTC	Neuphoria Therapeutics Inc. NEUP · Entity 7639	PurchaseCommon stock, $0.00001 par value per share	639,110	$5.14	$3,283,108.07	Disclosure SEC source: 0000902664-25-004536 · ownership.xml · nonDerivative · entry 1 Lynx1 Capital Management LP · CIK 0001910456 · 10% owner Nichols Weston · CIK 0001746376 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 875,328 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.96 to $5.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F2 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. Read SEC document
October 17, 2025 Filed Oct 21, 2025 23:00 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	PurchaseCommon Stock	32,217	$7.84	$252,565.17	Disclosure SEC source: 0000902664-25-004499 · ownership.xml · nonDerivative · entry 4 Lynx1 Capital Management LP · CIK 0001910456 · 10% owner Nichols Weston · CIK 0001746376 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 8,797,833 F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.78 to $7.85 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F2 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. Read SEC document
October 16, 2025 Filed Oct 21, 2025 23:00 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	PurchaseCommon Stock	150,000	$8.86	$1,328,250.00	Disclosure SEC source: 0000902664-25-004499 · ownership.xml · nonDerivative · entry 3 Lynx1 Capital Management LP · CIK 0001910456 · 10% owner Nichols Weston · CIK 0001746376 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 8,765,616 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.68 to $9.22 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F2 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. Read SEC document
October 15, 2025 Filed Oct 21, 2025 23:00 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	PurchaseCommon Stock	51,500	$7.94	$409,049.05	Disclosure SEC source: 0000902664-25-004499 · ownership.xml · nonDerivative · entry 2 Lynx1 Capital Management LP · CIK 0001910456 · 10% owner Nichols Weston · CIK 0001746376 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 8,615,616 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.88 to $8.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F2 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. Read SEC document
October 14, 2025 Filed Oct 21, 2025 23:00 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	PurchaseCommon stock, $0.0001 par value per share ("Common Stock")	15,032	$7.59	$114,047.78	Disclosure SEC source: 0000902664-25-004499 · ownership.xml · nonDerivative · entry 1 Lynx1 Capital Management LP · CIK 0001910456 · 10% owner Nichols Weston · CIK 0001746376 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 8,564,116 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.50 to $7.68 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F2 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. Read SEC document
October 10, 2025 Filed Oct 10, 2025 22:58 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	PurchaseCommon Stock	277,298	$7.36	$2,041,384.69	Disclosure SEC source: 0000902664-25-004379 · ownership.xml · nonDerivative · entry 3 Lynx1 Capital Management LP · CIK 0001910456 · 10% owner Nichols Weston · CIK 0001746376 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 8,549,084 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.87 to $7.46 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F2 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. Read SEC document
October 09, 2025 Filed Oct 10, 2025 22:58 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	PurchaseCommon Stock	626,043	$6.70	$4,191,858.72	Disclosure SEC source: 0000902664-25-004379 · ownership.xml · nonDerivative · entry 2 Lynx1 Capital Management LP · CIK 0001910456 · 10% owner Nichols Weston · CIK 0001746376 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 8,271,786 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.60 to $6.90 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F2 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. Read SEC document
October 08, 2025 Filed Oct 10, 2025 22:58 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	PurchaseCommon stock, $0.0001 par value per share ("Common Stock")	556,300	$6.46	$3,593,698.00	Disclosure SEC source: 0000902664-25-004379 · ownership.xml · nonDerivative · entry 1 Lynx1 Capital Management LP · CIK 0001910456 · 10% owner Nichols Weston · CIK 0001746376 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 7,645,743 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.40 to $6.60 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F2 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. Read SEC document
September 15, 2025 Filed Sep 16, 2025 00:05 UTC	Passage BIO, Inc. PASG · Entity 7829	PurchaseCommon Stock	11,900	$6.99	$83,175.05	Disclosure SEC source: 0000902664-25-004079 · ownership.xml · nonDerivative · entry 3 Lynx1 Capital Management LP · CIK 0001910456 · 10% owner Nichols Weston · CIK 0001746376 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 623,704 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.94 to $7.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F2 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. Read SEC document
September 12, 2025 Filed Sep 16, 2025 00:05 UTC	Passage BIO, Inc. PASG · Entity 7829	PurchaseCommon Stock	19,783	$6.99	$138,299.00	Disclosure SEC source: 0000902664-25-004079 · ownership.xml · nonDerivative · entry 2 Lynx1 Capital Management LP · CIK 0001910456 · 10% owner Nichols Weston · CIK 0001746376 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 611,804 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.93 to $7.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F2 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. Read SEC document
September 11, 2025 Filed Sep 16, 2025 00:05 UTC	Passage BIO, Inc. PASG · Entity 7829	PurchaseCommon stock, $0.0001 par value per share (Common Stock)	325	$6.96	$2,260.64	Disclosure SEC source: 0000902664-25-004079 · ownership.xml · nonDerivative · entry 1 Lynx1 Capital Management LP · CIK 0001910456 · 10% owner Nichols Weston · CIK 0001746376 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 592,021 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.915 to $6.985 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F2 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. Read SEC document
July 24, 2025 Filed Jul 24, 2025 22:12 UTC	Passage BIO, Inc. PASG · Entity 7829	PurchaseCommon Stock	66,423	$5.71	$379,454.67	Disclosure SEC source: 0000902664-25-003152 · ownership.xml · nonDerivative · entry 3 Lynx1 Capital Management LP · CIK 0001910456 · 10% owner Nichols Weston · CIK 0001746376 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 591,696 F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.535 to $5.9 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F3 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. Read SEC document
July 23, 2025 Filed Jul 24, 2025 22:12 UTC	Passage BIO, Inc. PASG · Entity 7829	PurchaseCommon Stock	49,302	$5.74	$283,032.92	Disclosure SEC source: 0000902664-25-003152 · ownership.xml · nonDerivative · entry 2 Lynx1 Capital Management LP · CIK 0001910456 · 10% owner Nichols Weston · CIK 0001746376 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 525,273 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.675 to $5.8 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F3 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. Read SEC document
July 22, 2025 Filed Jul 24, 2025 22:12 UTC	Passage BIO, Inc. PASG · Entity 7829	PurchaseCommon stock, $0.0001 par value per share ("Common Stock")	13,123	$5.44	$71,337.94	Disclosure SEC source: 0000902664-25-003152 · ownership.xml · nonDerivative · entry 1 Lynx1 Capital Management LP · CIK 0001910456 · 10% owner Nichols Weston · CIK 0001746376 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 475,971 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.33 to $5.475 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F2 · balance_after: The Reporting Persons' holdings have been adjusted to reflect the 1-for-20 reverse stock split of the Issuer effective on July 14, 2025, as disclosed on the Current Report on Form 8-K filed by the Issuer with the SEC on July 14, 2025. F3 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. Read SEC document
May 20, 2025 Filed May 21, 2025 20:49 UTC	TScan Therapeutics, Inc. TCRX · Entity 7255	PurchaseCommon Stock	1,200,000	$1.20	$1,440,000.00	Disclosure SEC source: 0000902664-25-002511 · ownership.xml · nonDerivative · entry 2 Lynx1 Capital Management LP · CIK 0001910456 · 10% owner Nichols Weston · CIK 0001746376 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 7,946,141 F1 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP and a managed account to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. Read SEC document
May 19, 2025 Filed May 21, 2025 20:49 UTC	TScan Therapeutics, Inc. TCRX · Entity 7255	PurchaseCommon stock, $0.0001 par value per share ("Common Stock")	1,388,794	$1.20	$1,666,552.80	Disclosure SEC source: 0000902664-25-002511 · ownership.xml · nonDerivative · entry 1 Lynx1 Capital Management LP · CIK 0001910456 · 10% owner Nichols Weston · CIK 0001746376 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 6,746,141 F1 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP and a managed account to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. Read SEC document
December 27, 2024 Filed Dec 31, 2024 21:05 UTC	Passage BIO, Inc. PASG · Entity 7829	PurchaseCommon stock, $0.0001 par value per share	373,645	$0.65	$241,038.39	Disclosure SEC source: 0000902664-24-007075 · ownership.xml · nonDerivative · entry 1 Lynx1 Capital Management LP · CIK 0001910456 · 10% owner Nichols Weston · CIK 0001746376 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 9,256,953 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6426 to $0.65 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F2 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. Read SEC document
December 26, 2024 Filed Dec 30, 2024 21:15 UTC	TScan Therapeutics, Inc. TCRX · Entity 7255	PurchasePre-funded Warrant (right to buy) · Derivative	7,500,000	$4.00 Strike: $0.00	$30,000,000.00	Disclosure SEC source: 0000902664-24-007064 · ownership.xml · derivative · entry 1 Lynx1 Capital Management LP · CIK 0001910456 · 10% owner Nichols Weston · CIK 0001746376 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 7,500,000 Underlying: Common Stock · 7,500,000 shares Expires not disclosed F1 · derivative.exercise_date: Subject to the terms and conditions set forth in the Pre-funded Warrant, the holder thereof may, at any time and from time to time on or after December 27, 2024, exercise the Pre-funded Warrant until it has been exercised in full. The Pre-funded Warrants reported herein contain an exercise limitation prohibiting the holder from exercising the Pre-Funded Warrants until such time as the holder, together with the Reporting Persons and certain other related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock (the "Blocker"). Due to the Blocker, the Pre-funded Warrants beneficially owned by the Reporting Persons are not presently exercisable. F1 · derivative.expiration_date: Subject to the terms and conditions set forth in the Pre-funded Warrant, the holder thereof may, at any time and from time to time on or after December 27, 2024, exercise the Pre-funded Warrant until it has been exercised in full. The Pre-funded Warrants reported herein contain an exercise limitation prohibiting the holder from exercising the Pre-Funded Warrants until such time as the holder, together with the Reporting Persons and certain other related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock (the "Blocker"). Due to the Blocker, the Pre-funded Warrants beneficially owned by the Reporting Persons are not presently exercisable. F2 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP and a managed account to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. Read SEC document
December 13, 2024 Filed Dec 16, 2024 21:26 UTC	TScan Therapeutics, Inc. TCRX · Entity 7255	PurchaseCommon Stock	100,000	$2.90	$290,140.00	Disclosure SEC source: 0000902664-24-006934 · ownership.xml · nonDerivative · entry 2 Lynx1 Capital Management LP · CIK 0001910456 · 10% owner Nichols Weston · CIK 0001746376 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 5,357,347 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.855 to $3.00, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F2 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. Read SEC document
December 12, 2024 Filed Dec 16, 2024 21:26 UTC	TScan Therapeutics, Inc. TCRX · Entity 7255	PurchaseCommon stock, $0.0001 par value per share ("Common Stock")	31,800	$3.01	$95,628.96	Disclosure SEC source: 0000902664-24-006934 · ownership.xml · nonDerivative · entry 1 Lynx1 Capital Management LP · CIK 0001910456 · 10% owner Nichols Weston · CIK 0001746376 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 5,257,347 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.99 to $3.03, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F2 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. Read SEC document
November 27, 2024 Filed Nov 27, 2024 23:11 UTC	Passage BIO, Inc. PASG · Entity 7829	PurchaseCommon Stock	29,300	$0.67	$19,663.23	Disclosure SEC source: 0000902664-24-006799 · ownership.xml · nonDerivative · entry 3 Lynx1 Capital Management LP · CIK 0001910456 · 10% owner Nichols Weston · CIK 0001746376 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 8,883,308 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.661 to $0.6838 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F2 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. Read SEC document
November 26, 2024 Filed Nov 27, 2024 23:11 UTC	Passage BIO, Inc. PASG · Entity 7829	PurchaseCommon Stock	167,055	$0.71	$118,191.41	Disclosure SEC source: 0000902664-24-006799 · ownership.xml · nonDerivative · entry 2 Lynx1 Capital Management LP · CIK 0001910456 · 10% owner Nichols Weston · CIK 0001746376 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 8,854,008 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.65 to $0.77 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F2 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. Read SEC document
November 25, 2024 Filed Nov 27, 2024 23:11 UTC	Passage BIO, Inc. PASG · Entity 7829	PurchaseCommon stock, $0.0001 par value per share ("Common Stock")	259,998	$0.56	$146,664.87	Disclosure SEC source: 0000902664-24-006799 · ownership.xml · nonDerivative · entry 1 Lynx1 Capital Management LP · CIK 0001910456 · 10% owner Nichols Weston · CIK 0001746376 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 8,686,953 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.49 to $0.65 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F2 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. Read SEC document
November 15, 2024 Filed Nov 19, 2024 21:26 UTC	TScan Therapeutics, Inc. TCRX · Entity 7255	PurchaseCommon stock, $0.0001 par value per share	947	$4.34	$4,113.96	Disclosure SEC source: 0000902664-24-006718 · ownership.xml · nonDerivative · entry 1 Lynx1 Capital Management LP · CIK 0001910456 · 10% owner Nichols Weston · CIK 0001746376 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 5,225,547 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.335 to $4.350, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F2 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. Read SEC document
April 19, 2024 Filed Apr 23, 2024 20:15 UTC	TScan Therapeutics, Inc. TCRX · Entity 7255	PurchasePre-funded Warrant (right to buy) · Derivative	5,000,000	$7.13 Strike: $0.00	$35,649,500.00	Disclosure SEC source: 0000902664-24-003030 · ownership.xml · derivative · entry 1 Lynx1 Capital Management LP · CIK 0001910456 · 10% owner Nichols Weston · CIK 0001746376 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 5,000,000 Underlying: Common Stock · 5,000,000 shares Expires not disclosed F1 · derivative.exercise_date: Subject to the terms and conditions set forth in the Pre-funded Warrant, the holder thereof may, at any time and from time to time on or after April 19, 2024, exercise the Pre-funded Warrant until it has been exercised in full. The Pre-funded Warrants reported herein contain an exercise limitation prohibiting the holder from exercising the Pre-Funded Warrants until such time as the holder, together with the Reporting Persons and certain other related parties, would not beneficially own after any such exercise more than 4.99% of the then issued and outstanding Common Stock (the "Blocker"). Due to the Blocker, the Pre-funded Warrants beneficially owned by the Reporting Persons are not presently exercisable. F1 · derivative.expiration_date: Subject to the terms and conditions set forth in the Pre-funded Warrant, the holder thereof may, at any time and from time to time on or after April 19, 2024, exercise the Pre-funded Warrant until it has been exercised in full. The Pre-funded Warrants reported herein contain an exercise limitation prohibiting the holder from exercising the Pre-Funded Warrants until such time as the holder, together with the Reporting Persons and certain other related parties, would not beneficially own after any such exercise more than 4.99% of the then issued and outstanding Common Stock (the "Blocker"). Due to the Blocker, the Pre-funded Warrants beneficially owned by the Reporting Persons are not presently exercisable. F2 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. Read SEC document
May 31, 2023 Filed Jun 2, 2023 21:35 UTC	TScan Therapeutics, Inc. TCRX · Entity 7255	SaleCommon Stock	400	$2.51	$1,003.00	Disclosure SEC source: 0000902664-23-003407 · ownership.xml · nonDerivative · entry 3 Lynx1 Capital Management LP · CIK 0001910456 · 10% owner Nichols Weston · CIK 0001746376 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 5,224,600 F1 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of ection 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. Read SEC document
May 31, 2023 Filed Jun 2, 2023 21:35 UTC	TScan Therapeutics, Inc. TCRX · Entity 7255	SaleCommon Stock	15,000	$2.52	$37,801.50	Disclosure SEC source: 0000902664-23-003407 · ownership.xml · nonDerivative · entry 2 Lynx1 Capital Management LP · CIK 0001910456 · 10% owner Nichols Weston · CIK 0001746376 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 5,225,000 F1 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of ection 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. Read SEC document
May 31, 2023 Filed Jun 2, 2023 21:35 UTC	TScan Therapeutics, Inc. TCRX · Entity 7255	SaleCommon stock, $0.0001 par value per share Common Stock	10,000	$2.51	$25,148.00	Disclosure SEC source: 0000902664-23-003407 · ownership.xml · nonDerivative · entry 1 Lynx1 Capital Management LP · CIK 0001910456 · 10% owner Nichols Weston · CIK 0001746376 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 5,240,000 F1 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of ection 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.